Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
John V HeymachDavid HarpoleTetsuya MitsudomiJanis M TaubeGabriella GalffyMaximilian HochmairThomas WinderRuslan ZukovGabriel GarbaosShugeng GaoHiroaki KurodaGyula OstorosTho V TranJian YouKang-Yun LeeLorenzo AntonuzzoZsolt Papai-SzekelyHiroaki AkamatsuBivas BiswasAlexander SpiraJeffrey CrawfordHa T LeMike AperghisGary J DohertyHelen MannTamer M FouadMartin Recknull nullPublished in: The New England journal of medicine (2023)
In patients with resectable NSCLC, perioperative durvalumab plus neoadjuvant chemotherapy was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone, with a safety profile that was consistent with the individual agents. (Funded by AstraZeneca; AEGEAN ClinicalTrials.gov number, NCT03800134.).